Table 1.
Patient and tumour characteristics*
| Factor | AR negative n = 32 (%) | AR positiven = 41 (%) |
|---|---|---|
| Age (years) | ||
| ≤35 | 1 (3.0) | 1 (2.4) |
| ≥35 | 31 (97.0) | 40 (97.6) |
| Estrogen receptor | ||
| Negative | 23 (72.0) | 9 (22.5) |
| Positive | 9 (28.0) | 31 (77.5) |
| Progesterone receptor | ||
| Negative | 27 (87.0) | 16 (39.0) |
| Positive | 4 (13.0) | 25 (61.0) |
| HER2 | ||
| Negative | 18 (85.7) | 25 (75.8) |
| Positive | 3 (14.3) | 8 (24.2) |
| Triple negativea | ||
| No | 6 (28.6) | 30 (90.9) |
| Yes | 15 (71.4) | 3 (9.1) |
*All patients were diagnosed with Stage III disease, as defined in the Materials and Methods section of the manuscript
aTriple negative breast cancer represents tumours displaying negative expression for estrogen receptor, progesterone receptor and HER2 by IHC. AR, androgen receptor; HER2, human epidermal growth factor receptor type 2.